Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy-Reference-Cited by-同舟云学术

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

Published:2006-06 Issue:6 Volume:7 Page:472-479
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Messing Edward M,Manola Judith,Yao Jorge,Kiernan Maureen,Crawford David,Wilding George,di'SantAgnese P Anthony,Trump Donald

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Treatment and survival of patients with cancer of the prostate;Surg Gyn Obstet,1967

2. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial;Bolla;Lancet,2002

3. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study;Granfors;J Urol,1998

4. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31;Pilepich;Int J Rad Onc Biol Phys,2005

5. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial;D'Amico;JAMA,2004

Cited by 786 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

2. Observation With or Without Subsequent Salvage Therapy for Pathologically Node-positive Prostate Cancer With Negative Conventional Imaging: Results From a Large Multicenter Cohort;European Urology Open Science;2024-10

3. Prostate cancer patients with lymphatic node involvement detected by immunohistochemistry. Is the effort worthwhile?;Urologic Oncology: Seminars and Original Investigations;2024-09

4. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent;European Urology;2024-08

5. PRIORITI: Phase 4 study of triptorelin or active surveillance in high‐risk prostate cancer;Asia-Pacific Journal of Clinical Oncology;2024-07-03